NICARDIPINE HYDROCHLORIDE

Post-LOE

nicardipine hydrochloride

Ichnos Glenmark Innovation

ANDAORALCAPSULE

Approved

Dec 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NICARDIPINE HYDROCHLORIDE (nicardipine hydrochloride) by Ichnos Glenmark Innovation is clinical pharmacology mechanism of action nicardipine hydrochloride is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. Approved for hypertension, hypertension. First approved in 2022.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Nicardipine hydrochloride is a calcium entry blocker (slow channel blocker or calcium ion antagonist) that inhibits the transmembrane influx of calcium ions into cardiac muscle and smooth muscle without changing serum calcium concentrations. The contractile…

Worked on NICARDIPINE HYDROCHLORIDE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NICARDIPINE HYDROCHLORIDE

Mechanism of Action

Indications (1)